Validity of Treatment for Patients with Head and Neck Squamous Cell Carcinoma with Distant Metastasis Detected at the First Examination

DOI Web Site Web Site 8 References
  • Takahashi Katsumasa
    Department of Otorhinolaryngology, Takasaki General Medical Center
  • Nishioka Yuki
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
  • Ida Shota
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
  • Kuwabara Yuki
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
  • Matsuyama Toshiyuki
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
  • Okamoto Ayako
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
  • Kuwabara Mikio
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
  • Shino Masato
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
  • Nikkuni Osamu
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
  • Kudo Takeshi
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
  • Takayasu Yukihiro
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
  • Chikamatsu Kazuaki
    Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine

Bibliographic Information

Other Title
  • 初診時に遠隔転移を伴う頭頸部扁平上皮癌に対する治療の妥当性
  • ショシンジ ニ エンカク テンイ オ トモナウ トウケイブ ヘンペイ ジョウヒ ガン ニ タイスル チリョウ ノ ダトウセイ

Search this article

Abstract

<p>　Data of a total of 35 patients with head and neck squamous cell carcinoma seen between 2007 and 2016, with distant metastases detected at the first examination were retrospectively reviewed. The median survival time of the 16 patients without any treatment (only best supportive care) was 87 days, while that of the 19 patients who received treatment was 343 days. There was a significant difference in the 1-year survival rate between the two groups (6% and 53%). The one-year survival rate in the palliative radiation group was very low (0%), and the median survival time was only 127 days. Chemotherapy, chemoradiotherapy, and molecular-targeted therapy improved the survival rate and prolonged the median survival time to over 350 days. Thus, even if a patient is diagnosed as having distant metastasis at the first examination, it should not be a reason to withhold treatment. Treatments for both the distant metastasis and primary tumor are recommended in such cases, taking comorbidities and adverse events associated with the treatment into account, because appropriate treatment has the potential to prolong the survival time.</p>

Journal

References(8)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top